BES2020 BES 2020 Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1-34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy (1 abstracts)
Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1–34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy
Fischler R *1 , Lecoq AL 2 , Besson F 2 , Briot K 3 , Salenave S 2 , Goujart C 2 , Leboulleux S , Carreira E 2 , Bricaire L 3 , Chabrolle C 5 , Corvilain B 1 , Philippe C 2 , Linglart A 2 , Grimon G 2 & Kamenicky P 2
1Erasme hospital, Brussels, BELGIUM; 2Bicêtre Hospital, Le Kremlin Bicêtre, FRANCE; 3Cochin Hospital, Paris, FRANCE; 4Institut Gustave Roussy, Villejuif, FRANCE; 5Leonardo da Vinci Health Center, Chambray-Lès-Tours, FRANCE
Introduction: Recombinant human parathyroid hormone (rPTH) (1–34) is prescribed off-label in France for patients with hypoparathyroidism resistant to conventional therapy. However, the bone impact of this long-term replacement therapy is not well known.
Objective: To determine the skeletal impact of chronic treatment with rPTH (1–34) in patients with hypoparathyroidism.
Design: Single-center prospective study. Patients treated for more than 2 years underwent Tc-99m MDP bone scintigraphy with early whole body image.
Results: 25 patients were treated with rPTH (1–34) for a median duration of 29 [IQR 25–75: 12–60.5] months. Median serum calcium was 2.08 [IQR 25–75: 2–2.21] mmol/l, indicative of a good calcium control. Seventeen patients received rPTH (1–34) for more than 2 years, 4 of whom developed diffuse osteo-articular pain. Bone scintigraphy, performed in 14 patients, revealed in 7 (50%) patients a bone hyperfixation evoking a ‘super bone scan’ usually seen in hyperparathyroidism. Bone hypermetabolism was not associated with pain but was accompanied by an increase in alkaline phosphatase (P<0.05). In 3 patients, treatment was stopped and the bone scan returned to normal after one year.
Conclusions: Long-term treatment with rPTH (1–34) may induce abnormal stimulation of bone cells despite an adequate control of hypocalcaemia, possibly due to the pharmacokinetics of the drug. Bone scintigraphy may be useful in detecting iatrogenic hyperparathyroidism in patients receiving long-term rhPTH (1–34).
Volume 71
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more